Hologic, Inc. (NASDAQ:HOLX) Receives $78.42 Average Target Price from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have been assigned an average recommendation of “Hold” from the fifteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $78.4167.

HOLX has been the subject of several research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective on the stock. in a research note on Friday, November 21st. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the company from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Morgan Stanley lifted their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th.

Hologic Stock Performance

NASDAQ HOLX opened at $75.35 on Friday. The company has a market capitalization of $16.82 billion, a PE ratio of 31.40, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. Hologic has a 52-week low of $51.90 and a 52-week high of $75.49. The company has a 50-day simple moving average of $74.93 and a 200 day simple moving average of $72.02.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the firm earned $0.87 earnings per share. The firm’s revenue was up 2.5% compared to the same quarter last year. On average, research analysts predict that Hologic will post 4.28 EPS for the current year.

Institutional Investors Weigh In On Hologic

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. increased its position in shares of Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after buying an additional 3,505,828 shares during the period. Illinois Municipal Retirement Fund grew its stake in Hologic by 20.4% during the third quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after acquiring an additional 29,143 shares in the last quarter. K.J. Harrison & Partners Inc purchased a new position in Hologic during the second quarter valued at approximately $1,987,000. Readystate Asset Management LP bought a new stake in Hologic during the 3rd quarter worth approximately $4,161,000. Finally, New York State Common Retirement Fund lifted its stake in Hologic by 16.3% in the 3rd quarter. New York State Common Retirement Fund now owns 142,622 shares of the medical equipment provider’s stock worth $9,626,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.